Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis

Research output: Contribution to journalArticle

Abstract

Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalActa medica Okayama
Volume73
Issue number2
Publication statusPublished - Jan 1 2019

Fingerprint

Hydrops Fetalis
Cytarabine
Down Syndrome
Newborn Infant
Acute Liver Failure
Liver
Leukemia
Transient Myeloproliferative Syndrome

Keywords

  • Cytarabine
  • Down syndrome
  • Exchange transfusion
  • Hydrops fetalis
  • Transient abnormal myelopoiesis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis. / Okamura, Tomoka; Washio, Yousuke; Yoshimoto, Junko; Tani, Kazumasa; Tsukahara, Hirokazu; Shimada, Akira.

In: Acta medica Okayama, Vol. 73, No. 2, 01.01.2019, p. 181-188.

Research output: Contribution to journalArticle

@article{ecc61f1fbcdb44f5871023578743a44b,
title = "Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis",
abstract = "Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.",
keywords = "Cytarabine, Down syndrome, Exchange transfusion, Hydrops fetalis, Transient abnormal myelopoiesis",
author = "Tomoka Okamura and Yousuke Washio and Junko Yoshimoto and Kazumasa Tani and Hirokazu Tsukahara and Akira Shimada",
year = "2019",
month = "1",
day = "1",
language = "English",
volume = "73",
pages = "181--188",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - Exchange transfusion and cytarabine for transient abnormal myelopoiesis in hydrops fetalis

AU - Okamura, Tomoka

AU - Washio, Yousuke

AU - Yoshimoto, Junko

AU - Tani, Kazumasa

AU - Tsukahara, Hirokazu

AU - Shimada, Akira

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.

AB - Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.

KW - Cytarabine

KW - Down syndrome

KW - Exchange transfusion

KW - Hydrops fetalis

KW - Transient abnormal myelopoiesis

UR - http://www.scopus.com/inward/record.url?scp=85064634095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064634095&partnerID=8YFLogxK

M3 - Article

C2 - 31015754

AN - SCOPUS:85064634095

VL - 73

SP - 181

EP - 188

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -